Camurus AB (publ) (OM: CAMX)
Health Care · Pharmaceuticals · SE
Skr641.00
+5.43% today · -7.0% 1Y
Camurus AB (publ) (OM: CAMX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.81B and employs 316 people.
Over the last twelve months the share price has lost 7.0%, trading between 430.80 and 710.00.
Tweenvest scores Camurus AB (publ) across four factors: quality 76/100, value 42/100, growth 100/100. Its strongest factor is growth.
CAMX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.81B
- Revenue (TTM)
- $233.87M
- P/E
- 56.69
- EPS
- 11.31
- Dividend yield
- —
- Beta (5Y)
- 0.43
- 52-week high
- Skr710.00
- 52-week low
- Skr430.80
- Avg volume (3M)
- —
- Shares outstanding
- 59.51M
- Employees
- 316
- Next earnings
- —
About Camurus AB (publ)
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
- ISIN
- SE0007692850
- Founded
- 1991
- Listed since
- Dec 3, 2015
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Yuhan CorporationKOSE: A000100 | $4.06B | ₩73,100.00 | -1.35% |
| J. B. Chemicals & Pharmaceuticals LimitedBSE: 506943 | $4.02B | Rs— | — |
| Zhejiang Huahai Pharmaceutical Co., Ltd.SHSE: 600521 | $3.88B | CN¥17.45 | +6.79% |
| Shijiazhuang Yiling Pharmaceutical Co., Ltd.SZSE: 002603 | $3.87B | CN¥15.53 | +1.17% |
| Hypera S.A.BOVESPA: HYPE3 | $3.81B | R$26.93 | +0.86% |
| Caliway Biopharmaceuticals Co., Ltd.TWSE: 6919 | $3.77B | NT$77.50 | -3.00% |
| Hubei Jumpcan Pharmaceutical Co., Ltd.SHSE: 600566 | $3.67B | CN¥26.70 | +2.61% |
| Regencell Bioscience Holdings LimitedNasdaqCM: RGC | $3.64B | $7.35 | +7.77% |
Figures last refreshed Oct 11, 2026.